Osimertinib Not Yet Recruiting Phase 2 Trials for Advanced Non-Small Cell Lung Cancer / EGFR T790M / Non-Small Cell Lung Cancer Stage IIIB Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03543683Combination of Osimertinib and Aspirin to Treat 1st Generation Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor(EGFR-TKI)Resistance Non-small Cell Lung Cancer ( NSCLC)
NCT03532698Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)